ATE265535T1 - Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen - Google Patents

Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Info

Publication number
ATE265535T1
ATE265535T1 AT01109013T AT01109013T ATE265535T1 AT E265535 T1 ATE265535 T1 AT E265535T1 AT 01109013 T AT01109013 T AT 01109013T AT 01109013 T AT01109013 T AT 01109013T AT E265535 T1 ATE265535 T1 AT E265535T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
infections caused
composition against
against tumors
papilloma viruses
Prior art date
Application number
AT01109013T
Other languages
German (de)
English (en)
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE265535(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE265535T1 publication Critical patent/ATE265535T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
AT01109013T 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen ATE265535T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Publications (1)

Publication Number Publication Date
ATE265535T1 true ATE265535T1 (de) 2004-05-15

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01109013T ATE265535T1 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
AT97935646T ATE205881T1 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97935646T ATE205881T1 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen

Country Status (12)

Country Link
EP (2) EP0862634B2 (enExample)
JP (2) JP4070815B2 (enExample)
AT (2) ATE265535T1 (enExample)
AU (1) AU736720B2 (enExample)
CA (1) CA2234263C (enExample)
DE (2) DE69728914T2 (enExample)
DK (2) DK1149910T3 (enExample)
ES (2) ES2215805T3 (enExample)
FR (1) FR2751879B1 (enExample)
HK (1) HK1043809B (enExample)
PT (2) PT1149910E (enExample)
WO (1) WO1998004705A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
WO2000000217A1 (fr) * 1998-06-26 2000-01-06 Aventis Pasteur Immunisation a ciblage mucosal
ES2671230T3 (es) 2006-06-20 2018-06-05 Transgene Sa Procedimiento para producir poxvirus y composiciones de poxvirus
HUE025015T2 (en) 2009-01-20 2016-04-28 Transgene Sa Soluble in ICAM-1 as a biomarker for predicting therapeutic response
DK2411815T3 (en) 2009-03-24 2015-11-30 Transgene Sa Biomarker MONITORING OF PATIENTS
US20120058493A1 (en) 2009-04-17 2012-03-08 Bruce Acres Biomarker for monitoring patients
SG176554A1 (en) 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
MX2012000979A (es) 2009-07-21 2012-06-08 Transgene Sa Composición enzimática para la digestión de embriones de pollo.
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
MX378901B (es) 2014-12-01 2025-03-10 Transgene Sa Formulaciones liquidas estables de virus de vacuna.
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
US11052147B2 (en) 2017-05-15 2021-07-06 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2020049151A1 (en) 2018-09-06 2020-03-12 Bavarian Nordic A/S Storage improved poxvirus compositions
US20230114464A1 (en) 2020-03-12 2023-04-13 Bavarian Nordic A/S Conditions Improving Poxvirus Stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
IE910909A1 (en) † 1990-03-20 1991-09-25 Behringwerke Ag Seroreactive epitopes of human Papillomavirus (HPV) 16¹proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DK1298211T3 (da) * 1991-07-19 2006-11-13 Univ Queensland Polynukleotidsegment af HPV16-genom
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
EP0789774A2 (en) * 1994-10-03 1997-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
DE69706825T2 (de) 2002-05-02
DE69706825D1 (de) 2001-10-25
EP0862634B2 (fr) 2006-03-01
PT862634E (pt) 2002-03-28
ES2215805T3 (es) 2004-10-16
DE69706825T3 (de) 2006-08-24
ATE205881T1 (de) 2001-10-15
HK1043809B (zh) 2004-12-03
AU736720B2 (en) 2001-08-02
ES2163795T3 (es) 2002-02-01
DE69728914T2 (de) 2005-04-07
AU3855297A (en) 1998-02-20
DK0862634T3 (da) 2002-01-21
CA2234263A1 (fr) 1998-02-05
FR2751879A1 (fr) 1998-02-06
PT1149910E (pt) 2004-09-30
DE69728914D1 (de) 2004-06-03
CA2234263C (fr) 2009-10-13
EP1149910B1 (fr) 2004-04-28
DK1149910T3 (da) 2004-08-02
DK0862634T4 (da) 2006-05-08
FR2751879B1 (fr) 1998-10-30
WO1998004705A1 (fr) 1998-02-05
JP2000500662A (ja) 2000-01-25
JP4198735B2 (ja) 2008-12-17
JP2007254474A (ja) 2007-10-04
JP4070815B2 (ja) 2008-04-02
HK1043809A1 (en) 2002-09-27
ES2163795T5 (es) 2006-07-16
EP0862634B1 (fr) 2001-09-19
EP0862634A1 (fr) 1998-09-09
EP1149910A1 (fr) 2001-10-31

Similar Documents

Publication Publication Date Title
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
TR199801179T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
EA199901031A1 (ru) Производные бензимидазола
PT696326E (pt) Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
RU95106674A (ru) Полиеновые соединения, фармацевтическая и косметическая композиция на их основе
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
ATE221059T1 (de) Delta 12,16-isotaxol analoge mit antineoplastischer wirkung und pharmazeutische zusammensetzungen sie enthaltend
ATE148630T1 (de) Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen
AU589939B2 (en) Medical composition for injection containing a spergualin as active ingredient and process for preparing the same
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
UA50808C2 (uk) Композиція для лікування респіраторного дистрес-синдрому дорослих або респіраторного дистрес-синдрому новонароджених
RU94043771A (ru) Замещенные бензимидазольные соединения, способ лечения, фармацевтическая композиция и способ получения бензимидазольных соединений
BG100930A (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
EP0932613A4 (en) EXPRESSION BLOCKING OF VIRULENT FACTORS IN S. AUREUS
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
NO971625L (no) Nye peptider med immunomodulatoriske effekter
ATE108437T1 (de) Substituierte diaminophthalimide und analoga.
DE69320339D1 (de) Derivate des Dolastatin
BR9908427A (pt) Composições farmacêuticas e uso das mesmas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1149910

Country of ref document: EP